{"entity":{"id":"ucart22","kind":"drug","name":"UCART22","aka":[],"tldr":"UCART22 is an experimental allogeneic CAR T-cell therapy from Cellectis S.A. in phase 2 trials for acute lymphoblastic leukaemia, aimed at CD22.","summary":"UCART22 is an allogeneic CAR T-cell therapy developed by Cellectis S.A.. Its target is CD22. The sponsor states: Gene-edited, donor-derived T cells engineered to recognise and attack CD22-positive leukaemia cells. ClinicalTrials.gov describes the intervention as: Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute lymphoblastic leukaemia. The largest, NCT04150497, plans to enrol 52 participants with primary completion was scheduled for 2026-06-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of UCART22","url":"https://clinicaltrials.gov/search?intr=UCART22"},{"label":"Sponsor page","url":"https://www.cellectis.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":["cd22"],"drugs":[],"companies":["cellectis"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04150497"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"allogeneic CAR T-cell therapy","mechanism":"Gene-edited, donor-derived T cells engineered to recognise and attack CD22-positive leukaemia cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ucart22/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"target":[{"id":"cd22","kind":"target","name":"CD22","route":"/targets/cd22/"}],"company":[{"id":"cellectis","kind":"company","name":"Cellectis","route":"/companies/cellectis/"}],"trial":[{"id":"nct04150497","kind":"trial","name":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","route":"/trials/nct04150497/"}]}}